Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:GERN News 12 December 2025

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation (NASDAQ: GERN) stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO (imetelstat) and its longer-term clinical ambitions. The headlines have been loud—one-third of the workforce is set to be cut, analysts are re-checking their models, and the market is weighing a familiar biotech question: is this the start of a leaner turnaround, or a sign that growth has stalled? Geron Corporation+2BioPharma Dive+2 As of the latest reported trading update on Dec. 12, GERN traded around $1.32, down about 5% on the day, after opening
12 December 2025
··

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop